

DCM Shriram Industries Limited

August 23, 2023

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long-term bank facilities	591.10	CARE A+ (RWN)	Placed on Rating Watch with Negative Implications
Short-term bank facilities	125.92	CARE A1+ (RWN)	Placed on Rating Watch with Negative Implications
Fixed deposit	15.00	CARE A+ (RWN)	Placed on Rating Watch with Negative Implications

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

CARE has placed the ratings of bank facilities and instrument of DCM Shriram Industries Limited (DSIL) on rating watch with Negative Implications. DSIL in its announcement to stock exchanges on August 14, 2023 has announced the board of directors' in-principle approval to undertake Composite Scheme of Arrangement wherein Lily Commercial Private Limited, a promoter company holding shares in the Company, will be merged with the Company. Also, to demerge the two business verticals of the Company, i.e., chemical undertaking and rayon undertaking (including defence and engineering projects) into two different companies, on a going concern basis, while the residual undertaking comprising of sugar, alcohol and power would be retained in DSIL. It was also intimated to exchange that each of these entities will be independently managed and controlled by separate promoter group families. The detailed scheme is being formulated and is yet to be submitted to the board for the approval.

CARE has taken note of the development and accordingly the ratings have been placed on the watch with negative implications as DSIL post restructuring will have lower scale of operations, lower margins and also will not have diversification benefit. Rayon and chemical busniess respectively contributed to 43% of topline and 69% of EBIT in FY23 However, considering that the scheme, post approval from the Board of Directors, will take close to 12-15 months for the necessary approvals; CARE will continue to monitor the developments related to the matter as well as its impact on company's operational and financial performance and will resolve the watch as DSIL gets necessary approvals and more clarity emerges on the impact of the same on the company.

The rating currently continue to derive its strength from experienced promoters and management team and long track record of operations, diversified revenue streams, healthy profitability and comfortable financial risk profile. However, these rating strengths are partially offset by the susceptibility of the revenues and profitability to the demand-supply dynamics, the susceptibility to agro-climatic conditions, and the cyclical and highly regulated nature of the industry.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Ability of the company to increase its scale of operations on a sustained basis along with improvement in its PBILDT margins to 12% on sustained basis.
- Total debt to EBITDA less than 2.6x on a sustained basis.
- Ability to improve the capital structure marked by overall gearing of less than 0.50x on a sustained basis

Negative factors

- Overall gearing greater than 1x on a sustained basis.
- Total debt/EBITDA over 4x on a sustained basis.

Analytical approach:

Standalone

Outlook: Not applicable

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications



Detailed description of the key rating drivers:

Key strengths

Diversified revenue streams: DSIL has a diversified business model and over the years it has been increasing its exposure to other segments like chemicals (capacity of 21,145 tonnes p.a.) and rayon (capacity of 17,055 tonnes p.a.). DSIL's sugar division is fully integrated with forward integration into cogeneration and distillery operations that de-risk the core sugar business of the company to an extent. The integrated nature of operations mitigates the volatility in sugar prices to some extent. During FY23 (refers to period from April 01 to March 31), the sugar division (including power and alcohol) contributed 56.55% to the total operating income, followed by chemical division 21.82% and industrial fibres division 21.64%. During FY23, around 100% of sugar cane crushed was towards B heavy molasses as against 63% in FY22. The increase in total income from operations is primarily driven by increased sales in the sugar segment from ₹839.98 crores in FY22 to ₹943.58 crores in FY23 mainly on account of higher realizations and increased sales in the chemical segment from ₹ 379.39 crores in FY22 to ₹455.08 crores in FY23 on account of higher domestic sales volume and realization as well. Parallelly, there was an increased focus on realizations in the agrochemical, fragrances and paint/ dye sectors. In FY23, DSIL achieved total operating income of ₹2,367.81 crore which increased by around 11% from ₹2,132.71 cr in FY22. However, the overall PBILDT margins remained rangebound between 7%-8% in FY23 mainly on account of higher raw material cost (owing to commodity inflation) in all segments.

CARE understands that there may be scaling down of operations with the current scheme of restructuring the company's operations and will monitor the changes in the revenue streams as better clarity emerges going forward.

Comfortable risk profile:

The capital structure of the company stood comfortable and improved marginally with long-term debt to equity and overall gearing ratios improved as on March 31, 2023 to 0.24x (PY: 0.34x) and 0.73x (0.91x) respectively. Also, interest coverage ratio as on March 31, 2023 improved with decreasing interest costs.

Going forward DSIL is not expected to incur substantial capex expense and rationalisation of its interest cost is going to benefit the company in terms of lower interest outgo and the coverage and solvency indicators are expected to improve going ahead.

Key weaknesses

Working capital intensive operations: The sugar industry being seasonal in nature has high working capital requirements during the peak season which is from November to April. The companies have high working capital requirements during the peak season to procure their primary raw material, i.e., sugarcane and manufacture sugar during this period. However, the company has de-risked its model by reducing dependence on sugar to a large extent. Current ratio declined to 1.17x (PY: 1.22x) as on March 31, 2023 and the company has sufficient buffer in the form of unutilised working capital facility available to it.

Exchange rate fluctuation risk: DSIL is exposed to foreign exchange risk as export sale from the chemical & rayon segment which together contributed approximately 23% of the total gross sales in FY23 (25% in FY22). DSIL primarily sells in Europe, China, USA, and Singapore, etc. It imports wood pulp from USA which is a raw material in rayon segment. DSIL has a natural hedge & apart from that, the company enters into forward contracts to hedge its forex exposure as and when required. DSIL had Rs. 99.26 crore (receivables) foreign currency exposure as on March 31, 2023 (₹80.22 cr as on March 31, 2022) and the complete amount stands naturally hedged.

Cyclical & regulated nature of sugar business: The industry is cyclical by nature and is vulnerable to the government policies for various reasons like its importance in the Wholesale Price Index (WPI) as it classifies as an essential commodity. DSIL's profitability, along with other UP-based sugar mills, continues to be vulnerable to the GoUP's policy on cane prices. The cane price is determined by the GoUP at the start of the crushing season. Thus, the company's performance can be impacted by a disproportionate increase in cane prices. Furthermore, its profitability remains vulnerable to the Government's policies on exports, MSP and remunerative ethanol prices. However, the recent measures taken by the Central Government and the GoUP supported sugar prices and the liquidity of sugar mills. Furthermore, healthy exports and higher diversion of sucrose towards ethanol in the recent years resulted in favorable demand-supply dynamics in the country, thus resulting in improved realisations currently. Over the long term, higher ethanol production with increased diversion towards B-heavy molasses and direct sugar juice by the industry is expected to help in curtailing the excess supply of sugar, resulting in lower volatility in sugar prices and cash flows from the sugar business.

Liquidity: Adequate

The liquidity profile of the company remains adequate with stable cash accruals from diversified revenue streams. The company has high inventory days as manufacturing of sugar takes place during November to April, while sales takes place uniformly during the complete year. The buyers are extended a credit period of 40-45 days while the creditors days are comparatively decreasing. Debtors and creditors as on April 30, 2023 are ₹51.98 crore (₹37.80 crore as on March 31, 2023) and ₹19.83 crore (₹20.32 crores as on March 31, 2023) respectively. Average utilization of the working capital limits at maximum level stood comfortable at around



77% in the past 12 months ended March 31, 2023. Current ratio declined to 1.18x (PY: 1.22x) as on March 31, 2023. The company generated healthy cash accruals of ₹96.15 cr in FY23 and has investments in Mutual Funds amounting to ₹28.35 crores, as on March 31, 2023. Gross cash accruals are expected to increase during FY24-FY26 and remain in the range of 130-160 crore. Against this, the company has repayment obligations of ₹76.01 crore, ₹69.07 crore and ₹45.71 crore for the years FY24, FY25 and FY26 respectively.

Environment, social, and governance (ESG) risks

Not Applicable

Applicable criteria

Policy on default recognition

Financial Ratios - Non financial Sector

Liquidity Analysis of Non-financial sector entities

Rating Outlook and Credit Watch

Short Term Instruments

Manufacturing Companies

Sugar

Policy on Withdrawal of Ratings

About the company and industry

Industry classification

Macro Economic Indicator	Sector	Industry	Basic Industry
Fast Moving Consumer Goods	Fast Moving Consumer Goods	Agricultural Food & other Products	Sugar

DSIL is a part of Dr Bansi Dhar Group, formed after the restructuring of the DCM Group in 1990. DSIL is currently engaged in manufacturing of sugar, alcohol, organic chemicals and industrial fibre. It has two integrated manufacturing plants, Daurala Sugar Complex and Daurala Organics in Daurala, Meerut (U.P.) with daily throughout of 12,500 tonnes of sugarcane crushed per day (TCD), a distillery with a capacity of 215 KL per day, a co-generation power plant with the power capacity of 94 MW and organic/ fine chemicals plant with total installed capacity of 21,145 tonnes per annum (increased from 20,931 tonnes per annum) as on March 31, 2023. The company has another manufacturing unit, 'Shriram Rayons' at Kota for the manufacturing and export of rayon tyre cord, yarn and fabric to tyre manufacture₹ It has a total installed capacity for industrial fibres of 17,055 tonnes per year which includes yarn production capacity, grey fabric and dipped fabric capacity.

DSIL has also ventured into defence equipment manufacturing to explore the opportunities following the Government of India's 'Make in India' initiative and opening up of defence production to private sector. In light of this, the company had entered into an agreement with Zyrone Dynamics Havacilik Danismanlik Ve Ar-Ge San. Tic. A.S. (ZD), a Turkish company, for technological support for two variants of UAVs and both the parties will support each other in marketing the products in India and globally. As per the agreement, DCM would subscribe to 30% of the capital of the foreign company comprising of 25,715 shares at a total investment of just over USD 1.05 million (around ₹8 crores) in five tranches over a period of about a year, subject to necessary approval with regard to foreign investment under Foreign Exchange Management Act (FEMA) Regulations. Until FY23, DSIL has invested ₹3.14 crore as on March 31, 2023, representing 9,797 shares i.e. 38% of total investment.

Brief Financials (₹ crore)	March 31, 2022 (A)	March 31, 2023 (A)	June 30, 2023 (UA)
Total operating income	2,132.71	2,357.69	527.80
PBILDT	151.80	149.49	63.13
PAT	65.74	60.26	27.08
Overall gearing (times)	0.91	0.73	NA
Interest coverage (times)	3.78	4.47	5.59

UA: Unaudited, A: Audited; Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA:

Not Applicable



Any other information:

Not Applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM- YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fixed Deposit		-	-	-	15.00	CARE A+; RWN
Fund-based - LT-Cash Credit		-	-	-	448.80	CARE A+; RWN
Fund-based - LT-Term Loan		-	-	31/03/2028	142.30	CARE A+; RWN
Non-fund- based-Short Term		-	-	-	125.92	CARE A1+; RWN



Annexure-2: Rating history for the last three years

		Current Ratings		Rating History				
Name of the Sr. No. Instrument/Bank Facilities		Туре	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2023- 2024	Date(s) and Rating(s) assigned in 2022- 2023	Date(s) and Rating(s) assigned in 2021- 2022	Date(s) and Rating(s) assigned in 2020- 2021
1	Fund-based - LT- Term Loan	LT	142.30	CARE A+; RWN	1)CARE A+; Stable (05-Jul- 23)	1)CARE A+; Stable (23-Sep- 22)	1)CARE A+; Stable (18-Sep- 21)	1)CARE A+; Stable (28-Sep- 20)
2	Fund-based - LT- Cash Credit	LT	448.80	CARE A+; RWN	1)CARE A+; Stable (05-Jul- 23)	1)CARE A+; Stable (23-Sep- 22)	1)CARE A+; Stable (18-Sep- 21)	1)CARE A+; Stable (28-Sep- 20)
3	Non-fund-based- Short Term	ST	125.92	CARE A1+; RWN	1)CARE A1+ (05-Jul- 23)	1)CARE A1+ (23-Sep- 22)	1)CARE A1+ (18-Sep- 21)	1)CARE A1+ (28-Sep- 20)
4	Fixed Deposit	LT	15.00	CARE A+; RWN	1)CARE A+; Stable (05-Jul- 23)	1)CARE A+; Stable (23-Sep- 22) 2)CARE A+; Stable (22-Jun- 22)	1)CARE A+ (FD); Stable (18-Sep- 21)	1)CARE A+ (FD); Stable (28-Sep- 20)

^{*}Long term/Short term.

Annexure-3: Detailed explanation of covenants of the rated instruments/facilities

Not Applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fixed Deposit	Simple
2	Fund-based - LT-Cash Credit	Simple
3	Fund-based - LT-Term Loan	Simple
4	Non-fund-based-Short Term	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please click here

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.



Contact Us

Media Contact

Mradul Mishra Director

CARE Ratings Limited Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

Relationship Contact

Dinesh Sharma Director

CARE Ratings Limited Phone: +91-11-4533 3200

E-mail: dinesh.sharma@careedge.in

Analytical Contacts

Pulkit Agarwal Director

CARE Ratings Limited Phone: +91-22-6754 3505

E-mail: pulkit.agarwal@careedge.in

Ravleen Sethi Associate Director **CARE Ratings Limited** Phone: +91-11-4533 3251

E-mail: rayleen.sethi@careedge.in

Akanksha Bansal Lead Analyst

CARE Ratings Limited

E-mail: akanksha.bansal@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant facto₹ CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For the detailed Rationale Report and subscription information, please visit www.careedge.in